The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study
Xiao‐Feng Le(The University of Texas MD Anderson Cancer Center), Jia Wu(The University of Texas MD Anderson Cancer Center), Surbhi Singhal(International Society of Nephrology), Nikki Myall(Stanford University), Don L. Gibbons(The University of Texas MD Anderson Cancer Center), Kai Yin(Guangdong Academy of Medical Sciences), Yijin Wu(Anhui Medical University), Fangdi Sun(Stanford University), Ke Pan(The University of Texas MD Anderson Cancer Center), Joel W. Neal(Stanford Medicine), Heather A. Wakelee(Palo Alto Institute), John V. Heymach(The University of Texas MD Anderson Cancer Center), Ara A. Vaporciyan(The University of Texas MD Anderson Cancer Center), Hai T. Tran(The University of Texas MD Anderson Cancer Center), Hai‐Yan Tu(Jiangnan University), Libo Tang(Guangdong Academy of Medical Sciences), David S.P. Tan(National University of Singapore), Alfredo Addeo, M Borgeaud(University Hospital of Geneva), Maria Nilsson(The University of Texas MD Anderson Cancer Center), Jes Chauviere Lee(The University of Texas MD Anderson Cancer Center), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Jonathan W. Riess(University of California Davis Medical Center), Tingxia Zhang(Second Affiliated Hospital of Zhejiang University), Aaron C. Tan(Baker Heart and Diabetes Institute), Wen Li(First Affiliated Hospital of Xi'an Jiaotong University), Jianjun Zhang(Shanghai Jiao Tong University), Yongsheng Li(First People's Hospital of Yunnan Province), R Z Zhang(Central South University), Xinran Dong(Children's Hospital of Fudan University), W Ringsurongkawong(The University of Texas MD Anderson Cancer Center)
Cited by 9
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k